These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15138569

  • 1. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group.
    Toma S, Bonelli L, Sartoris A, Mira E, Antonelli A, Beatrice F, Giordano C, Benazzo M, Caroggio A, Cavalot AL, Gandolfo S, Garozzo A, Margarino G, Schenone G, Spadini N, Sirotovà Z, Zibordi F, Balzarini F, Serafini I, Miani P, Cortesina G.
    Oncol Rep; 2004 Jun; 11(6):1297-305. PubMed ID: 15138569
    [Abstract] [Full Text] [Related]

  • 2. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
    Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK.
    J Clin Oncol; 2001 Jun 15; 19(12):3010-7. PubMed ID: 11408495
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Chemoprevention of head and neck cancer with retinoids: a negative result.
    Perry CF, Stevens M, Rabie I, Yarker ME, Cochrane J, Perry E, Traficante R, Coman W.
    Arch Otolaryngol Head Neck Surg; 2005 Mar 15; 131(3):198-203. PubMed ID: 15781758
    [Abstract] [Full Text] [Related]

  • 7. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
    Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X.
    Clin Cancer Res; 2012 Jul 01; 18(13):3705-13. PubMed ID: 22577058
    [Abstract] [Full Text] [Related]

  • 8. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
    Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM.
    J Clin Oncol; 1995 Aug 01; 13(8):1950-7. PubMed ID: 7636535
    [Abstract] [Full Text] [Related]

  • 9. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnait F, Rappersberger K, Pilarski P, Pehamberger H, European Cooperative Adjuvant Melanoma Treatment Study Group.
    J Clin Oncol; 2005 Dec 01; 23(34):8655-63. PubMed ID: 16260701
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
    Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK.
    J Natl Cancer Inst; 2006 Apr 05; 98(7):441-50. PubMed ID: 16595780
    [Abstract] [Full Text] [Related]

  • 11. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M.
    J Clin Oncol; 2000 Aug 05; 18(16):2972-80. PubMed ID: 10944130
    [Abstract] [Full Text] [Related]

  • 12. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.
    Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ.
    N Engl J Med; 1990 Sep 20; 323(12):795-801. PubMed ID: 2202902
    [Abstract] [Full Text] [Related]

  • 13. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
    Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK.
    Cancer Epidemiol Biomarkers Prev; 2001 Aug 20; 10(8):823-9. PubMed ID: 11489748
    [Abstract] [Full Text] [Related]

  • 14. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
    Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L.
    J Clin Oncol; 2010 Jun 20; 28(18):2989-95. PubMed ID: 20479425
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy.
    Cascinu S, Del Ferro E, Ligi M, Graziano F, Castellani A, Catalano G.
    Ann Oncol; 1996 Jul 20; 7(5):538. PubMed ID: 8839916
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study.
    Nikolaou AC, Fountzilas G, Daniilidis I.
    J Laryngol Otol; 1996 Sep 20; 110(9):857-61. PubMed ID: 8949297
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up.
    Seixas-Silva JA, Richards T, Khuri FR, Wieand HS, Kim E, Murphy B, Francisco M, Hong WK, Shin DM.
    Arch Otolaryngol Head Neck Surg; 2005 Apr 20; 131(4):304-7. PubMed ID: 15837897
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ.
    J Clin Oncol; 2005 Jun 20; 23(18):4172-8. PubMed ID: 15961764
    [Abstract] [Full Text] [Related]

  • 20. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Fesneau M, Pointreau Y, Chapet S, Martin L, Pommier P, Alfonsi M, Laguerre B, Feham N, Berger C, Garaud P, Calais G.
    Int J Radiat Oncol Biol Phys; 2010 Jan 01; 76(1):154-63. PubMed ID: 19386430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.